<DOC>
	<DOC>NCT01644968</DOC>
	<brief_summary>This study is designed to determine the safety and highest tolerated dose of anti-OX40 in patients with advanced cancer.</brief_summary>
	<brief_title>Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer</brief_title>
	<detailed_description>This study will evaluate the safety and determine the maximal tolerated dose of anti-OX40; evaluated the immune response to the study treatment; measure the pharmacokinetics of anti-OX40; monitor tumor regression, and identify the most biologically active dose of anti-OX40 to induce antigen-specific responses to a variety of immunogens.</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients with uncurable metastatic carcinoma, lymphoma, or sarcoma. ECOG performance status 0, 1, 2 No active bleeding No clinical coagulopathy Anticipated lifespan greater than 12 weeks Active residual toxicity from prior therapies Active Infection HIV positive Hepatitis B or C positive Pregnant or nursing women Requirement for oral steroids Brain metastases Presence or history of autoimmune disease Shellfish or tetanus allergy Splenomegaly Lymph nodes greater than 10 cm in maximal diameter Uncontrolled angina or class II or IV heart failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>metastatic carcinoma</keyword>
	<keyword>lymphoma</keyword>
	<keyword>sarcoma</keyword>
	<keyword>anti-OX40</keyword>
</DOC>